Serge Lepage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Serge Lepage has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Abdul Al-Hesayen
St Michael's Hospital, Toronto, Ontario, Canada
2 shared publicationsAdam Grzeslo
Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
2 shared publicationsBruce Sussex
Memorial University, St John's, Newfoundland and Labrador, Canada
2 shared publicationsGeorge A. Heckman
Schlegel-University of Waterloo Research Institute for Aging, University of Waterloo, Waterloo, Ontario, Canada
2 shared publicationsHeather J. Ross
Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
2 shared publicationsJonathan G. Howlett
Cumming School of Medicine, University of Calgary, Libin Cardiovascular Institute, Calgary, Alberta, Canada
2 shared publications
Latest Publications
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e037899
In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial
Background: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in‐hospital. Thus, this prespecified PARAGLIDE‐HF (Prospective Comparison of ARNI With ARB Given Following Stabilization In Decompensated HFpEF) analysis assessed the effects of Sac/Val versus valsartan (Val) by location of initiation in HF with ejection fraction >40% and recent worsening HF. Methods and Results: This analysis of the double‐blind, randomized controlled trial assessed patients by in‐hospital and out‐of‐hospital (≤30 days of worsening HF) initiation. The primary end point was time‐averaged proportional change in NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) from baseline through weeks 4 and 8. A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NT‐proBNP change. Safety end points were symptomatic hypotension, hyperkalemia, and worsening renal function. Overall, 324 (70%, 162 Sac/Val, 162 Val) were initiated in‐hospital and 142 (71 Sac/Val, 71 Val) out‐of‐hospital. There was no evidence of a statistically significant differential treatment benefit of Sac/Val versus Val on NT‐proBNP change by location of initiation (in‐hospital, 0.86 [95% CI, 0.70–1.05] and out‐of‐hospital, 0.87 [95% CI, 0.70–1.09]; P interaction =0.99). The win ratio for the hierarchical outcome was 1.09 (95% CI, 0.82–1.45; P =0.57) for in‐hospital and 1.43 (95% CI, 0.91–2.26; P =0.12) for out‐of‐hospital. For the safety end points of symptomatic hypotension, hyperkalemia, and worsening renal function, no statistically significant differences in tolerability were seen between in‐hospital and out‐hospital initiation ( P interaction >0.1). Conclusions: Sac/Val provided consistent benefit compared with Val, whether initiated in‐hospital or out‐of‐hospital in HF with ejection fraction >40% with a recent worsening HF event, demonstrating an opportunity to improve postdischarge outcomes by initiating Sac/Val during hospitalization.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e037899
Open AccessIn‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial
Background: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in‐hospital. Thus, this prespecified PARAGLIDE‐HF (Prospective Comparison of ARNI With ARB Given Following Stabilization In Decompensated HFpEF) analysis assessed the effects of Sac/Val versus valsartan (Val) by location of initiation in HF with ejection fraction >40% and recent worsening HF. Methods and Results: This analysis of the double‐blind, randomized controlled trial assessed patients by in‐hospital and out‐of‐hospital (≤30 days of worsening HF) initiation. The primary end point was time‐averaged proportional change in NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) from baseline through weeks 4 and 8. A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NT‐proBNP change. Safety end points were symptomatic hypotension, hyperkalemia, and worsening renal function. Overall, 324 (70%, 162 Sac/Val, 162 Val) were initiated in‐hospital and 142 (71 Sac/Val, 71 Val) out‐of‐hospital. There was no evidence of a statistically significant differential treatment benefit of Sac/Val versus Val on NT‐proBNP change by location of initiation (in‐hospital, 0.86 [95% CI, 0.70–1.05] and out‐of‐hospital, 0.87 [95% CI, 0.70–1.09]; P interaction =0.99). The win ratio for the hierarchical outcome was 1.09 (95% CI, 0.82–1.45; P =0.57) for in‐hospital and 1.43 (95% CI, 0.91–2.26; P =0.12) for out‐of‐hospital. For the safety end points of symptomatic hypotension, hyperkalemia, and worsening renal function, no statistically significant differences in tolerability were seen between in‐hospital and out‐hospital initiation ( P interaction >0.1). Conclusions: Sac/Val provided consistent benefit compared with Val, whether initiated in‐hospital or out‐of‐hospital in HF with ejection fraction >40% with a recent worsening HF event, demonstrating an opportunity to improve postdischarge outcomes by initiating Sac/Val during hospitalization.
- Open Access
- 13 March 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (10) , E391-E397
Prévention et traitement de l’hyperkaliémie chez les patients sous inhibiteurs du système rénine–angiotensine–aldostérone
- 13 March 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (10) , E391-E397
Open AccessPrévention et traitement de l’hyperkaliémie chez les patients sous inhibiteurs du système rénine–angiotensine–aldostérone
- 1 February 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (2) , 159-169
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
- 1 February 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (2) , 159-169
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
- 1 February 2016
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 32 (2) , 148-50
Heart Failure, Iron Deficiency, and Supplementation: Where Do We Stand?
- 1 February 2016
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 32 (2) , 148-50
Heart Failure, Iron Deficiency, and Supplementation: Where Do We Stand?
- Open Access
- 1 December 2015
- Published by Hindawi Limited in Case Reports in Cardiology
- Vol. 2015, 1-3
A Heart Stopping Case of the Bezold-Jarisch Reflex
The Bezold-Jarisch reflex is a parasympathetic reflex induced by intense mechanical stimulation of the ventricular myocytes. Exceptionally, cases have been described in patients receiving dobutamine infusion during a stress echocardiography. All were healthy middle-aged women and recovered without sequelae. A healthy 60-year-old woman suffered two 5.9-second episodes of asystole during her 20 mcg/kg/min infusion of dobutamine. Recovery was quick and without sequelae. Echocardiography and coronary angiography were both normal. In conclusion, this is the fourth documented case of a severe Bezold-Jarisch reflex causing asystole during dobutamine infusion. Diagnosis can only be made after excluding all other possible diagnoses, most importantly ischemia. This serves as a reminder of the importance of close monitoring during dobutamine infusion.
- 1 December 2015
- Published by Hindawi Limited in Case Reports in Cardiology
- Vol. 2015, 1-3
Open AccessA Heart Stopping Case of the Bezold-Jarisch Reflex
The Bezold-Jarisch reflex is a parasympathetic reflex induced by intense mechanical stimulation of the ventricular myocytes. Exceptionally, cases have been described in patients receiving dobutamine infusion during a stress echocardiography. All were healthy middle-aged women and recovered without sequelae. A healthy 60-year-old woman suffered two 5.9-second episodes of asystole during her 20 mcg/kg/min infusion of dobutamine. Recovery was quick and without sequelae. Echocardiography and coronary angiography were both normal. In conclusion, this is the fourth documented case of a severe Bezold-Jarisch reflex causing asystole during dobutamine infusion. Diagnosis can only be made after excluding all other possible diagnoses, most importantly ischemia. This serves as a reminder of the importance of close monitoring during dobutamine infusion.
- 1 January 2015
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 31 (1) , 3-16
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications
- 1 January 2015
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 31 (1) , 3-16
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications
- 1 June 2013
- Published by SAGE Publications in Journal of Women's Health
- Vol. 22 (6) , 526-531
Gender and Other Disparities in Referral to Specialized Heart Failure Clinics Following Emergency Department Visits
Persons with heart failure (HF) at high risk for adverse events should be followed by specialized HF clinics, since follow-up by specialized HF clinics improves outcomes for HF patients. The objective was to determine whether there were disparities for gender and other factors associated with referral of patients to specialized HF clinics. In this prospective cohort study, patients with a confirmed primary diagnosis of HF were recruited by nurses at 8 hospital emergency departments (ED) in Québec, Canada. They were interviewed by telephone at 6 weeks post ED discharge and subsequently at 3 months and 6 months. Pertinent clinical variables were extracted from medical charts by trained nurses. Bivariate analysis and multiple logistic regression were used to identify whether gender and other potential factors were associated with referral to the HF clinic. We enrolled 549 patients (mean age 75.5±11.0 years; 51% males). By 6 months after their ED visit for HF, 37.6% of the cohort were referred to specialized HF clinics. Men were more likely to be referred (odds ratio [OR] 2.04; 95% confidence interval [CI] 1.12, 3.74). Other factors associated with referral were younger age (OR 0.95; 95% CI 0.92, 0.98), and systolic dysfunction HF (left ventricle ejection fraction <40%) (OR 3.08; 95% CI 1.77, 5.46). There are disparities in referral with respect to gender, age, and type of HF. These disparities in referral need to be addressed.
- 1 June 2013
- Published by SAGE Publications in Journal of Women's Health
- Vol. 22 (6) , 526-531
Gender and Other Disparities in Referral to Specialized Heart Failure Clinics Following Emergency Department Visits
Persons with heart failure (HF) at high risk for adverse events should be followed by specialized HF clinics, since follow-up by specialized HF clinics improves outcomes for HF patients. The objective was to determine whether there were disparities for gender and other factors associated with referral of patients to specialized HF clinics. In this prospective cohort study, patients with a confirmed primary diagnosis of HF were recruited by nurses at 8 hospital emergency departments (ED) in Québec, Canada. They were interviewed by telephone at 6 weeks post ED discharge and subsequently at 3 months and 6 months. Pertinent clinical variables were extracted from medical charts by trained nurses. Bivariate analysis and multiple logistic regression were used to identify whether gender and other potential factors were associated with referral to the HF clinic. We enrolled 549 patients (mean age 75.5±11.0 years; 51% males). By 6 months after their ED visit for HF, 37.6% of the cohort were referred to specialized HF clinics. Men were more likely to be referred (odds ratio [OR] 2.04; 95% confidence interval [CI] 1.12, 3.74). Other factors associated with referral were younger age (OR 0.95; 95% CI 0.92, 0.98), and systolic dysfunction HF (left ventricle ejection fraction <40%) (OR 3.08; 95% CI 1.77, 5.46). There are disparities in referral with respect to gender, age, and type of HF. These disparities in referral need to be addressed.
- 1 October 1997
- Published by Elsevier in Atherosclerosis
- Vol. 134 (1-2) , 215
3.P.78 Increased resistance of LDL subfractions to oxidation in severe hypercholesterolemic patients treated with LDL-apheresis
- 1 October 1997
- Published by Elsevier in Atherosclerosis
- Vol. 134 (1-2) , 215
3.P.78 Increased resistance of LDL subfractions to oxidation in severe hypercholesterolemic patients treated with LDL-apheresis